← Back to Screener
BioMarin Pharmaceuticals Inc (BMRN)
Price$54.88
Favorite Metrics
Price vs S&P 500 (26W)-4.31%
Price vs S&P 500 (4W)-8.55%
Market Capitalization$10.57B
P/E Ratio (Annual)30.31x
All Metrics
P/CF (Annual)12.77x
Book Value / Share (Quarterly)$31.65
P/TBV (Annual)1.98x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)15.40%
Cash Flow / Share (Quarterly)$3.73
Price vs S&P 500 (YTD)-12.20%
Gross Margin (TTM)81.43%
Net Profit Margin (TTM)10.83%
EPS (TTM)$1.76
10-Day Avg Trading Volume1.50M
EPS Excl Extra (TTM)$1.76
Revenue Growth (5Y)11.60%
EPS (Annual)$1.77
ROI (Annual)5.22%
Gross Margin (Annual)81.43%
Net Profit Margin (5Y Avg)7.20%
Cash / Share (Quarterly)$8.12
P/E Basic Excl Extra (TTM)30.31x
Revenue Growth QoQ (YoY)17.03%
EPS Growth (5Y)-16.98%
P/E Normalized (Annual)30.31x
ROA (Last FY)4.59%
Revenue Growth TTM (YoY)12.87%
EBITD / Share (TTM)$2.25
ROE (5Y Avg)3.65%
Operating Margin (TTM)12.71%
Cash Flow / Share (Annual)$3.73
P/B Ratio1.74x
P/B Ratio (Quarterly)1.88x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)3.06x
Net Interest Coverage (TTM)-21.18x
ROA (TTM)4.68%
EV / EBITDA (TTM)22.52x
EPS Incl Extra (Annual)$1.77
Current Ratio (Annual)5.21x
Quick Ratio (Quarterly)3.50x
3-Month Avg Trading Volume2.29M
52-Week Price Return-7.11%
EV / Free Cash Flow (Annual)13.75x
P/E Incl Extra (TTM)30.31x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$30.54
P/S Ratio (Annual)3.28x
Asset Turnover (Annual)0.42x
52-Week High$66.28
Operating Margin (5Y Avg)8.01%
EPS Excl Extra (Annual)$1.77
CapEx CAGR (5Y)-4.20%
Tangible BV CAGR (5Y)9.35%
26-Week Price Return4.43%
Quick Ratio (Annual)3.50x
13-Week Price Return-2.57%
Total Debt / Equity (Annual)0.10x
Current Ratio (Quarterly)5.21x
Enterprise Value$9,860.397
Revenue / Share Growth (5Y)10.95%
Asset Turnover (TTM)0.43x
Book Value / Share Growth (5Y)6.97%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)0.47x
Pretax Margin (Annual)14.98%
Cash / Share (Annual)$8.12
3-Month Return Std Dev26.62%
Gross Margin (5Y Avg)78.11%
Net Income / Employee (TTM)$0
EBITDA CAGR (5Y)68.23%
ROE (Last FY)5.73%
Net Interest Coverage (Annual)10.23x
EPS Basic Excl Extra (Annual)$1.77
P/FCF (TTM)14.75x
Receivables Turnover (TTM)4.11x
EV / Free Cash Flow (TTM)13.75x
Total Debt / Equity (Quarterly)0.10x
EPS Incl Extra (TTM)$1.76
Receivables Turnover (Annual)4.11x
ROI (TTM)5.30%
P/S Ratio (TTM)3.28x
Pretax Margin (5Y Avg)8.96%
Revenue / Share (Annual)$16.32
Tangible BV / Share (Annual)$29.99
Forward P/E12.68x
Price vs S&P 500 (52W)-42.20%
P/E Ratio (TTM)30.31x
EPS Growth TTM (YoY)-18.09%
Year-to-Date Return-8.06%
5-Day Price Return-0.44%
EPS Normalized (Annual)$1.77
ROA (5Y Avg)2.86%
Net Profit Margin (Annual)10.83%
Month-to-Date Return-3.27%
Cash Flow / Share (TTM)$1.30
EBITD / Share (Annual)$2.22
EPS Growth (3Y)33.12%
Operating Margin (Annual)12.71%
LT Debt / Equity (Annual)0.10x
P/CF (TTM)12.77x
ROI (5Y Avg)3.22%
P/E Excl Extra (TTM)30.31x
LT Debt / Equity (Quarterly)0.10x
EPS Basic Excl Extra (TTM)$1.76
P/TBV (Quarterly)1.94x
P/B Ratio (Annual)1.88x
Inventory Turnover (TTM)0.47x
Pretax Margin (TTM)14.98%
Book Value / Share (Annual)$31.65
Price vs S&P 500 (13W)-5.43%
Net Margin Growth (5Y)-25.18%
Beta0.25x
P/FCF (Annual)14.75x
Revenue / Share (TTM)$16.76
ROE (TTM)5.82%
52-Week Low$50.76
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.09
4.06
4.06
4.13
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
BMRNBioMarin Pharmaceuticals Inc | 3.28x | 12.87% | 81.43% | -16.98% | $54.88 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
BioMarin Pharmaceutical develops therapies for rare genetic diseases, specializing in enzyme replacement and gene therapies. The company has eight approved treatments for achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. An early-stage pipeline targets additional skeletal conditions and enzyme-based therapies.